摘要
目的探讨雌激素和孕激素受体及P16蛋白在乳腺癌组织中的表达与预后.方法选取行腺癌根治术并接受内分泌辅助治疗的原发性乳腺癌患者140例,免疫组化法检测乳腺癌组织中雌激素受体、孕激素受体、P16蛋白表达情况;收集患者年龄、月经情况、组织学分级、肿瘤直径、病灶分化程度、病理类型等临床病理指标;乳腺癌根治术后给予患者为期3 a的随访,记录生存情况.结果 140例乳腺癌患者组织中雌激素受体阳性58例(41.43%),孕激素受体阳性60例(42.56%),P16阳性82例(58.57%).不同年龄、月经状态、分化程度的乳腺癌患者雌激素受体、孕激素受体阳性率差异均具有统计学意义(P<0.05).多因素Cox回归分析显示:年龄>40岁、组织学分级Ⅲ期、低分化程度是乳腺癌患者生存率的独立危险因素;乳腺癌组织中雌激素受体阳性、孕激素受体阳性、P16蛋白阴性是乳腺癌患者生存率的独立保护因素.结论雌激素和孕激素受体及P16蛋白表达与乳腺癌患者预后明显相关,可用于内分泌辅助治疗预后的判断; P16基因可能参与调控乳腺癌内分泌辅助治疗的疗效.
Objective To investigate the expression of estrogen,progesterone receptor and P16 protein and prognosis in breast cancer.Method 140 patients with primary breast cancer who underwent radical resection of adenocarcinoma and received endocrine adjuvant therapy were selected.The expression of estrogen receptor,progesterone receptor and P16 protein in breast cancer tissues were detected by immunohistochemistry.Age,menstruation,histological grade and swelling were collected.Patients were followed up for 3 years to record survival rate after radical mastectomy.Results In 140 cases of breast cancer,58 cases of estrogen receptor(41.4 3%)were positive,60 cases of progesterone receptor(42.56%)were positive and 82 cases(58.57%)were P16 positive.The positive rates of estrogen receptor and progesterone receptor in breast cancer patients with different ages,menstrual status and differentiation degree were significantly different(P<0.0 5);Multivariate Cox regression analysis showed that age>40 years old,histological grade III and low differentiation were independent risk factors for survival rate of breast cancer patients;positive estrogen receptor,progesterone receptor and negative P16 protein in breast cancer tissues were independent protective factors for survival rate of breast cancer patients.Conclusion The expression of estrogen,progesterone receptor and P16 protein is significantly related to the prognosis of breast cancer patients,which can be used to judge the prognosis of endocrine adjuvant therapy.P16 gene may be involved in regulating the efficacy of endocrine adjuvant therapy for breast cancer.
作者
张雪云
Zhang Xueyun(Affiliated Hospital of Qinghai University,Xining 810001,China)
出处
《北华大学学报（自然科学版）》
CAS
2019年第3期328-332,共5页
Journal of Beihua University（Natural Science）
基金
青海省自然科学基金重点项目(2014-Z-938Q)
青海大学附属医院中青年科研基金项目(ASRF-2015-YB-09)
关键词
乳腺癌
雌激素受体
孕激素受体
P16蛋白
breast cancer
estrogen receptor
progesterone receptor
P16 protein
